These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25682970)

  • 41. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA; Prata MM
    Rev Port Cardiol; 2007 Nov; 26(11):1173-82. PubMed ID: 18297839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
    Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
    Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment prospects for autosomal-dominant polycystic kidney disease.
    Qian Q; Harris PC; Torres VE
    Kidney Int; 2001 Jun; 59(6):2005-22. PubMed ID: 11380803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Practical approach to patient therapy affected by Autosomal Dominant Autosomic Polycystic Kidney Disease].
    Esposito C; La Milia V; Altobelli C; Cerutti R; Manunta P; Dallera N; Piscopo G; Magistroni R
    G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
    LaRiviere WB; Irazabal MV; Torres VE
    Transl Res; 2015 Apr; 165(4):488-98. PubMed ID: 25438190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
    Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
    BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.
    Santoro D; Pellicanò V; Visconti L; Trifirò G; Buemi M; Cernaro V
    Expert Opin Investig Drugs; 2015; 24(9):1199-218. PubMed ID: 26125126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease.
    Ramanathan G; Elumalai R; Periyasamy S; Lakkakula B
    Iran J Kidney Dis; 2014 Jul; 8(4):265-77. PubMed ID: 25001132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease.
    Haseebuddin M; Tanagho YS; Millar M; Roytman T; Chen C; Clayman RV; Miller B; Desai A; Benway B; Bhayani S; Figenshau RS
    J Urol; 2012 Oct; 188(4):1239-44. PubMed ID: 22902029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel targets for the treatment of autosomal dominant polycystic kidney disease.
    Belibi FA; Edelstein CL
    Expert Opin Investig Drugs; 2010 Mar; 19(3):315-28. PubMed ID: 20141351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
    Ecder T; Schrier RW
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):369-74. PubMed ID: 15151483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autosomal dominant polycystic kidney disease: time for a change?
    Chapman AB
    J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autosomal dominant policystic kidney disease, more than a renal disease.
    Torra R
    Minerva Endocrinol; 2014 Jun; 39(2):79-87. PubMed ID: 24736482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colchicine treatment in autosomal dominant polycystic kidney disease: many points in common.
    Solak Y; Atalay H; Polat I; Biyik Z
    Med Hypotheses; 2010 Feb; 74(2):314-7. PubMed ID: 19765912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A; Elhassan E; Schrier RW
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autosomal dominant polycystic kidney disease and the heart and brain.
    Krishnappa V; Vinod P; Deverakonda D; Raina R
    Cleve Clin J Med; 2017 Jun; 84(6):471-481. PubMed ID: 28628430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.